Travere Therapeutics' market cap has more than doubled in six months, reflecting confidence in FILSPARI's role in treating ...
Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Travere Therapeutics (NasdaqGM:TVTX) ...
Investor's Business Daily on MSN
Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025
Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, ...
Renalys Pharma reports positive results from phase III study of sparsentan in Japanese patients with IgA nephropathy: Tokyo, Japan Friday, November 28, 2025, 13:00 Hrs [IST] Renal ...
In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine ...
Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies.
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm ...
As I shared in last week's report, the dip buying opportunity in markets was capitalized upon last week. Both the S&P 500 and ...
Rio Tinto Group is planning to sell its US boron assets, which could be valued at up to $2 billion, according to a Bloomberg report on Wednesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results